GlassScriptPhysician profile
Tova Rogers
NPI 1356872246
$2,131.21
in general payments reported to CMS, 2019-2025
19 companies · $1,138 in 2025
The $1,138 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.01 · 2022: $79.17 · 2023: $460 · 2024: $439 · 2025: $1,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,505 · Consulting Fee: $450 · Education: $82.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,505.08 |
| Consulting Fee | $450.00 |
| Education | $82.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $499.16 | 2023-2025 | Adbry |
| Abbvie INC. | $309.50 | 2021-2025 | Skyrizi, Rinvoq |
| Genzyme Corporation | $251.90 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $235.04 | 2022-2025 | Ilumya |
| Organon LLC | $183.71 | 2025 | Vtama, Nexplanon |
| Janssen Biotech, INC. | $133.26 | 2023-2024 | Tremfya |
| Novartis Pharmaceuticals Corporation | $101.91 | 2022-2025 | |
| Galderma Laboratories, L.P. | $68.67 | 2023-2025 | Nemluvio |
| Ucb, INC. | $58.32 | 2023-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $44.02 | 2022-2024 | Taltz, Olumiant |
| Regeneron Healthcare Solutions, INC. | $35.77 | 2023-2024 | Dupixent |
| Incyte Corporation | $35.68 | 2023 | Opzelura |
| Dermavant Sciences, INC. | $35.61 | 2023 | Vtama |
| Pfizer INC. | $34.75 | 2024-2025 | |
| Amgen INC. | $33.91 | 2023 | Otezla |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $20.86 | 2024 | Xolair |
| Stimlabs LLC | $17.93 | 2025 | Allacor P |
| E.R. Squibb & Sons, L.L.C. | $16.00 | 2024 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $15.21 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tova Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.